High Levels of Granzyme B Expression in Invasive Cervical Carcinoma Correlates to Poor Response to Treatment

REFERENCES

• Pisani P., Bray F., Parkin D. M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002; 97: 72–81
   PubMed Web of Science ®Google Scholar
• Villa L. L. Human papillomaviruses and cervical cancer. Adv Cancer Res 1997; 71: 321–341
   PubMed Web of Science ®Google Scholar
• zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342–350
   PubMed Web of Science ®Google Scholar
• Johnson J. C., Burnett A. F., Willet G. D., Young M. A., Doniger J. High frequency of latent and clinical human papillomavirus cervical infections in immunocompromised human immunodeficiency virus-infected women. Obstet Gynecol 1992; 79: 321–327
   PubMed Web of Science ®Google Scholar
• Slavik J. M., Hutchcroft J. E., Bierer B. E. CD28/CTLA-4 and CD80/CD86 families: signaling and function. Immunol Res 1999; 19: 1–2
   PubMed Web of Science ®Google Scholar
• Sharpe A. H., Freeman G. J. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2: 116–126
   PubMed Web of Science ®Google Scholar
• Hodi F. S., Mihm M. C., Soiffer R. J., Haluska F. G., Butler M., Seiden M. V., Davis T., Henry-Spires R., MacRae S., Willman A., Padera R., Jaklitsch M. T., Shankar S., Chen T. C., Korman A., Allison J. P., Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U SA 2003; 100: 4712–4717
   PubMed Web of Science ®Google Scholar
• Kondo M. C., Ribalta J. C., da Silva I. D., Alves M. T., de Azevedo G. R., Focchi N. V., Martins J., Granzyme B. Focchi as a prognostic marker of cervical intraepithelial neoplasia. Eur J Gynaecol Oncol 2005; 26: 87–89
   PubMed Web of Science ®Google Scholar
• Bontkes H. J., de Gruijl T. D., Walboomers J. M., van den Muysenberg A. J., Gunther A. W., Scheper R. J., Meijer C. J., Kummer J. A. Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br J Cancer 1997; 76: 1353–1360
   PubMed Web of Science ®Google Scholar
• Waggoner S. E. Cervical cancer. Lancet 2003; 361: 2217–2225
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Cervical Cancer. Clinical Practice Guidelines in Oncology 2006; version 1, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site Available in
   Google Scholar
• Pecorelli S., Odicino F. Cervical cancer staging. Cancer J 2003; 9: 390–394
   PubMed Web of Science ®Google Scholar
• Jain D., Srinivasan R., Patel F. D., Kumari G. S. Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol Oncol 2003; 88: 22–28
   PubMed Web of Science ®Google Scholar
• Ishikawa H., Sakurai H., Hasegawa M., Mitsuhashi N., Takahashi M., Masuda N., Nakajima M., Kitamoto Y., Saitoh J., Nakano T. Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2004; 60: 513–521
   PubMed Web of Science ®Google Scholar
• Trapani J. A., Smyth M. J. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002; 2: 735–747
   PubMed Web of Science ®Google Scholar
• Shulzhenko N., Yambartsev A., Goncalves-Primo A., Gerbase-DeLima M., Morgun A. Selection of control genes for quantitative RT-PCR based on microarray data. Biochem Biophys Res Commun 2005; 337: 306–312
   PubMed Web of Science ®Google Scholar
• Ludwig J. A., Weinstein J. N. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005; 5: 845–856
   PubMed Web of Science ®Google Scholar
• Dalton W. S., Friend S. H. Cancer biomarkers–an invitation to the table. Science 2006; 312: 1165–1168
   PubMed Web of Science ®Google Scholar
• Strand C., Enell J., Hedenfalk I., Fernö M. RNA quality in frozen breast cancer samples and the influence on gene expression analysis: a comparison of three evaluation methods using microcapillary electrophoresis traces. Mol Biol 2007; 8: 38–47
   Google Scholar
• Auer H., Lyianarachchi S., Newsom D., Klisovic M. I., Marcucci G., Kornacker K. Chipping away at the chip bias: RNA degradation in microarray analysis. Nat Genet 2003; 35: 292–293
   PubMed Web of Science ®Google Scholar
• Skrypina N. A., Timofeeva A. V., Khaspekov G. L., Savochkina L. P., Beabealashvilli R Sh, Total R NA. suitable for molecular biology analysis. J Biotechnol 2003; 105: 1–9
   PubMed Web of Science ®Google Scholar
• Kondratiev S., Sabo E., Yakirevich E., Lavie O., Resnick M. B. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 2004; 10: 4450–4456
   PubMed Web of Science ®Google Scholar
• ten Berge R. L., Dukers D. F., Oudejans J. J., Pulford K., Ossenkoppele G. J., de Jong D., Misere J. F., Meijer C. J. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood 1999; 93: 2688–2696
   PubMed Web of Science ®Google Scholar
• Oudejans J. J., Jiwa N. M., Kummer J. A., Ossenkoppele G. J., van Heerde P., Baars J. W., Kluin P. M., Kluin-Nelemans J. C., van Diest P. J., Middeldorp J. M., Meijer C. J. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997; 89: 1376–1382
   PubMed Web of Science ®Google Scholar
• ten Berge R. L., Oudejans J. J., Dukers D. F., Meijer J. W., Ossenkoppele G. J., Meijer C. J. Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker. Leukemia 2001; 15: 458–464
   PubMed Web of Science ®Google Scholar
• Oudejans J. J., Harijadi H., Kummer J. A., Tan I. B., Bloemena E., Middeldorp J. M., Bladergroen B., Dukers D. F., Vos W., Meijer C. J. High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent. J Pathol 2002; 198: 468–475
   PubMed Web of Science ®Google Scholar
• Bird P. I. Regulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins. Immunol Cell Biol 1999; 77: 47–57
   PubMed Web of Science ®Google Scholar
• Medema J. P., de Jong J., Peltenburg L. T., Verdegaal E. M., Gorter A., Bres S. A., Franken K. L., Hahne M., Albar J. P., Melief C. J., Offringa R. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U SA 2001; 98: 11515–11520
   PubMed Web of Science ®Google Scholar
• Kemper C., Chan A. C., Green J. M., Brett K. A., Murphy K. M., Atkinson J. P. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003; 421: 388–392
   PubMed Web of Science ®Google Scholar
• Grossman W. J., Verbsky J. W., Tollefsen B. L., Kemper C., Atkinson J. P., Ley T. J. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004; 104: 2840–2848
   PubMed Web of Science ®Google Scholar
• Gondek D. C., Lu L. F., Quezada S. A., Sakaguchi S., Noelle R. J. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005; 174: 1783–1786
   PubMed Web of Science ®Google Scholar
• Cao X., Cai S. F., Fehniger T. A., Song J., Collins L. I., Piwnica-Worms D. R., Ley T. J., Granzyme B. and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27: 635–646
   PubMed Web of Science ®Google Scholar
• Woo E. Y., Chu C. S., Goletz T. J., Schlienger K., Yeh H., Coukos G., Rubin S. C., Kaiser L. R., June C. H. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766–4772
   PubMed Web of Science ®Google Scholar
• Liyanage U. K., Moore T. T., Joo H. G., Tanaka Y., Herrmann V., Doherty G., Drebin J. A., Strasberg S. M., Eberlein T. J., Goedegebuure P. S., Linehan D. C. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756–2761
   PubMed Web of Science ®Google Scholar
• Marshall N. A., Christie L. E., Munro L. R., Culligan D. J., Johnston P. W., Barker R. N., Vickers M. A. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103: 1755–1762
   PubMed Web of Science ®Google Scholar